How to Obtain AMA
PRA Category 1
Credit™
- Listen to the audio discussion.
- Take the CME posttest.
- Login to your account.
- Complete the registration / evaluation form.
- Print your personalized
CME certificate.
|
|
|
Long-Term Safety and Efficacy of DMARDs and Biologics in the
Treatment of Rheumatoid Arthritis |
| |
| Release Date: March 22, 2010 |
Expiration Date: March 22, 2011 |
Technical Requirements
(will appear in new window)
| Estimated Time of Completion |
1 hour |
| Description / Overview |
The purpose of this activity is to review evidence for the long-term safety and efficacy of disease-modifying antirheumatic drugs (DMARDs) and biologics for the treatment of rheumatoid arthritis (RA). |
| Objectives |
On completion of this activity, participants should be able to:
- Assess the long-term efficacy and appropriate measures of response for DMARDs and biologics in the treatment of RA.
- Describe the long-term safety and appropriate monitoring for a patient with RA treated with DMARDs or biologics.
- Discuss factors that impact the choice of therapy in a patient with early RA.
|
| Target Audience |
This activity is directed to rheumatologists and primary care physicians who treat patients with RA. |
| Accreditation |
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit. |
Activity Director |
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, Ohio |
Faculty |
Roy Fleischmann, MD
Clinical Professor of Medicine
University of Texas Southwestern Medical Center
Medical Director
Metroplex Clinical Research Center
Dallas, Texas |
| Disclosures |
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty has indicated that he may have a relationship, which in the context of his presentation(s), could be perceived as a potential conflict of interest:
| Leonard Calabrese, DO |
| |
Consulting: |
Abbott Laboratories;
Amgen Inc.; Centocor, Inc.; Elan Pharmaceuticals, Inc.;
Genentech, Inc.; Roche Laboratories, Inc. |
| |
| |
Research: |
Centocor, Inc. |
| |
| |
Teaching
and Speaking: |
Amgen Inc.; Genentech, Inc. |
| |
| Roy Fleischmann, MD |
| |
Consulting: |
Abbott Laboratories; Amgen Inc.; Biogen Idec; Bristol-Myers Squibb Company; Centocor Ortho Biotech Services, Inc.; Genentech, Inc.; Lexicon Pharmaceuticals, Inc.; Eli Lilly and Company; Pfizer Inc; Roche Laboratories, Inc.; UCB |
| |
| |
Independent Contractor: |
Abbott Laboratories; Amgen Inc.; Biogen Idec; Bristol-Myers Squibb Company; Centocor Ortho Biotech Services, Inc.; Genentech, Inc.; Lexicon Pharmaceuticals, Inc.; Eli Lilly and Company; Pfizer Inc; Roche Laboratories, Inc.; UCB |
| |
| |
Membership on advisory committee or review panels: |
Abbott Laboratories; Amgen Inc.; Biogen Idec; Bristol-Myers Squibb Company; Centocor Ortho Biotech Services, Inc.; Genentech, Inc.; Lexicon Pharmaceuticals, Inc.; Eli Lilly and Company; Pfizer Inc; Roche Laboratories, Inc.; UCB |
|
The Cleveland Clinic Foundation Center for Continuing Education
acknowledges:
This activity is supported by an educational donation provided by Amgen.
This activity is supported by an educational grant from Bristol-Myers Squibb Company.
This activity is supported by an educational grant from Centocor Ortho Biotech Services.
This activity is supported by an independent educational grant from Roche Laboratories, Inc.
This CME activity was produced by
The Cleveland Clinic Foundation
Center for Continuing Education,
the RJ Fasenmyer Center for Clinical Immunology and DIME.
CME Disclaimer
The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.
|
